← SynDRA
MOMELOTINIB
SynDRA canonical compound SYN0021364 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | JAK1 | JAK2 | JAK3 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
All known targets
- JAK1
- JAK2
- ACVR1
- JAK3
- TYK2
Mechanisms of action (all sources)
- JAK1 INHIBITOR
- Tyrosine-protein kinase JAK1 inhibitor
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- ACVR1 INHIBITOR
- Activin receptor type-1 inhibitor
- JAK3 INHIBITOR
- TYK2 INHIBITOR
- JAK inhibitor
- JAK2 MODULATOR
- JAK1 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- MAPK10
- NTRK1
- NEK9
- NEK3
- NEK1
- MYLK2
- MUSK
- MST1R
- MINK1
- MERTK
- MARK3
- MARK2
- MARK1
- MAPK9
- MAPK8
- MAPK1
- CSNK2A2
- MAP4K2
- MAP3K9
- MAP3K8
- ABL1
- KDR
- IKBKE
- IKBKB
- HIPK4
- HIPK1
- HDAC1
- GRK4
- GAK
- FGR
- FECH
- NTRK2
- OPA1
- PAK4
- PDGFRA
- YES1
- ULK3
- TYRO3
- TSSK1B
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ATXN2
- CCNB1
- CDK5R1
- HLA-B
- HLAB
- IFNB1
- IFNG
- KSYK
- NR1I3
- NSD2
- PRKAB1
- TP53
Drug classes
- Antineoplastic Agents
- Janus Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- OJJAARA
- Ojjaara
- CYT-387
- CYT-0387
- CYT-11387
- CYT387
- GS-0387
- Cyt387
- CYT 387
- CYT 11387
- UNII-6O01GMS00P
- 6O01GMS00P
- CHEMBL1078178
- AK102858
- CYT387 sulfate salt
- momelotinibum
- CHEBI:91407
- RefChem:819199
- DTXCID30200399
- Momelotinib (CYT387)
- MFCD16038899
- Momelotinib [USAN]
- C23H22N6O2
- Momelotinib [USAN:INN]
- Omjjara
- MOMELOTINIB [INN]
- Momelotinib (USAN/INN)
- MOMELOTINIB [WHO-DD]
- MLS006011154
- GTPL7791
- orb1307329
- SCHEMBL2237234
- SCHEMBL29352115
- EX-A260
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N
- GLXC-03525
- HMS3244K19
- HMS3244K20
Look up MOMELOTINIB in the interactive SynDRA portal →